For example, metastatic bladder cancer and esophageal cancer with a high expression of ACSS2 are more prone to developing cisplatin resistance, while the use of ACSS2 inhibitors in culture medium can reduce the drug resistance developed during cisplatin treatment [32,38]. Here, ACSS2 is linked to esophageal cancer.